Cite
39 Notch2 promotes bladder cancer progression: Pre-clinical rationale for a novel targeted therapy.
MLA
Hayashi, T., et al. “39 Notch2 Promotes Bladder Cancer Progression: Pre-Clinical Rationale for a Novel Targeted Therapy.” European Urology Supplements, vol. 13, no. 1, Apr. 2014, p. e39. EBSCOhost, https://doi.org/10.1016/S1569-9056(14)60041-5.
APA
Hayashi, T., Gust, K. M., Jäger, W., Awrey, S., Li, N., Altamirano-Dimas, M., Buttyan, R., Fazli, L., Matsubara, A., & Black, P. C. (2014). 39 Notch2 promotes bladder cancer progression: Pre-clinical rationale for a novel targeted therapy. European Urology Supplements, 13(1), e39. https://doi.org/10.1016/S1569-9056(14)60041-5
Chicago
Hayashi, T., K.M. Gust, W. Jäger, S. Awrey, N. Li, M. Altamirano-Dimas, R. Buttyan, L. Fazli, A. Matsubara, and P.C. Black. 2014. “39 Notch2 Promotes Bladder Cancer Progression: Pre-Clinical Rationale for a Novel Targeted Therapy.” European Urology Supplements 13 (1): e39. doi:10.1016/S1569-9056(14)60041-5.